Barriers to advancement The study found that having less favourable conditions for expenditure in an innovative biotech sector may be actively discouraging its growth. Most Chinese biopharmaceutical businesses sell generic drugs and do not invest in R&D. These hybrid business versions have fallen out of favor in the west, where venture capitalists prefer a well-defined targeted strategy over a mix of models that mitigate industrial risk. As price-structured competition among domestic manufacturers continues to put pressure on profit margins, even fewer firms might be able to support in-home R&D programs.Normally this receptor is not found on blood vessels with the exception of the reproductive organs, where it really is present in lower concentrations than in tumors, said the American and French experts. Related StoriesNew RNA test of blood platelets may be used to identify location of cancerMeat-rich diet plan may increase kidney malignancy riskMD Anderson research reveals why chemotherapy drugs not effective for most pancreatic cancer patientsThe group discovered that activation of the FSH receptor plays a part in the signaling of a proteins that stimulates the growth of blood vessels, including those in tumors.